• Chun-Wei Lu, Chun-Bing Chen, Tsu-Man Chiu, Chih-Chiang Chen, Kai-Che Wei, Shang-Hung Lin, Sebastian Yu, Chao-Kai Hsu, Pa-Fan Hsiao, Pei-Sung Hsu, Jian Su, Sheau-Chiou Chao, Cheng-Ta Yang, Wen-Hung Chung, and Yung-Hung Luo.
• Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan; Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan.
• J Formos Med Assoc. 2024 Aug 21.

AbstractThe 2023 consensus from the Taiwanese Dermatological Association (TDA) and Taiwan Lung Cancer Society (TLCS) addresses the management of tyrosine kinase inhibitor (TKI)-induced skin toxicities in non-small cell lung cancer (NSCLC). Providing a comprehensive overview, the consensus reflects recent advances in understanding causes and developmental processes of TKI-related skin toxicities. Aimed at guiding clinicians in Taiwan, the consensus integrates new treatment perspectives while incorporating experiences from local dermatology experts. Recommendations underwent a voting process, achieving consensus when 75% or more of experts agreed, leading to their inclusion. Approved by over 90% of participants, the recommended treatment algorithms for major skin toxicities offer valuable insights for clinicians managing TKI-associated effects in NSCLC patients.Copyright © 2024 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.

3 keywords...

hide…